EyePoint Appoints Michael Campbell as Chief Commercial Officer
EyePoint, Inc. (EYPT)
Last eyepoint, inc. earnings: 3/5 07:00 am
Check Earnings Report
Company Research
Source: GlobeNewswire
– Seasoned commercial executive with over 30 years of leadership in retinal disease across biotech and large pharma –– Brings established track record of successful product launches and oversight of prominent ophthalmology franchises, including Lucentis® and Xiidra® – WATERTOWN, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Michael Campbell has been appointed Chief Commercial Officer. Mr. Campbell, an experienced commercial leader with a proven track record of successful product launches and oversight of prominent ophthalmology franchises, will assume responsibility for EyePoint’s commercial strategy and launch readiness for DURAVYU™ (vorolanib intravitreal insert), currently in Phase 3 development for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Mr. Campbell w
Show less
Read more
Impact Snapshot
Event Time:
EYPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EYPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EYPT alerts
High impacting EyePoint, Inc. news events
Weekly update
A roundup of the hottest topics
EYPT
News
- EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026GlobeNewswire
- EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026 [Yahoo! Finance]Yahoo! Finance
- EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026GlobeNewswire
EYPT
Earnings
- 11/5/25 - Miss
EYPT
Analyst Actions
- 11/26/25 - Cantor Fitzgerald
EYPT
Sec Filings
- 2/18/26 - Form 4
- 2/17/26 - Form SCHEDULE
- 2/12/26 - Form SCHEDULE
- EYPT's page on the SEC website